LA DEPRESSIONE NEL LONG COVID: ASPETTI CLINICI E TERAPEUTICI

Gabriele Sani

Fondazione Policlinico Universitario «A. Gemelli» IRCCS Università Cattolica del Sacro Cuore



Editorial

n the spring of 2013, Eileen Barrett, MD, MPH. lost a colleague to suicide. The two worked at the Indian Health Service's Gal-Jun Indian Medical Center in New Mexico where Barrett was the deputy chief of medi-

Medical News & Perspectives

Jennifer Abbasi

+

cine. Even before the tragic event. Audio she saw workers struggle under administrative burdens and hold themselves personally responsible for

problems outside of their control. With her coworker's death it became painfully clear that clinician wellness had to become a higher priority. "It made me really think that we needed to do more for everybody on the health care team," Barrett, now an associate professor of medicine and an academic hospitalist at the University of New Mexico in Albuquerque, said in a recent interview with JAMA.

As the school's director of graduate medical education wellness initiatives. Barrett has spent a lot of time focusing on physician care since the coronavirus disease 2019 (COVID-19) pandemic began. She wants phy-



more than 1200 health care workers in China JAMA: What are some of the key stressors and their mental health outcomes. They that physicians are dealing with during found that there were specific risk factors for

Mental Health and the Covid-19 Pandemic

isolation

Betty Pfefferbaum, M.D., J.D., and Carol S. North, M.D., M.P.E.

Mental health: time to invest in quality

The theme of this year's World Mental Health Day,

on Oct 10, is increased investment in mental health.

Why invest, and why now? The answer is simple. At

the best of times, good mental health is needed for

a society to thrive. During a pandemic, good mental

health is more important than ever. Without a focus

on mental health, any response to COVID-19 will be

deficient, reducing individual and societal resilience,

2020 has been a difficult year for mental health

and impeding social, economic, and cultural recovery.

ncertain prognoses, looming severe shortages of resources for testing and treatment and for protecting responders and health care providers from infection, imposition of unfamiliar public health measures that infringe on personal freedoms, large and growing financial losswith es, and conflicting messages from vider authorities are among the major stressors that undoubtedly will contribute to widespread emotional distress and increased risk

terms of quality. For example, great strides have been

made in the delivery of telepsychiatry over the past

10 months; individuals who receive these services must

be instrumental in their future use and development.

This involvement will ensure that telepsychiatry is

used in an intelligent, targeted manner that provides

appropriate support, rather than being a cost-saving,

one-size-fits-all measure that risks exacerbating

health inequalities or inadvertently reinforcing social

for p

addre

come

respc

Pu

N ENGL J MED 383;6 NEJM.ORG AUGUST 6, 2020

COVID-19 and psychiatrists' responsibilities: a WPA position paper

The SARS-CoV-2 virus has changed our world, endangering health, lives, social connections and economies¹, with the likelihood and consequences of future waves of infection still unknown. In this context, the WPA Standing Committee on Ethics and Review has produced a position paper to provide ethical guidance to the profession on the issues raised by the pandemic². This essay summarizes and builds on this position paper, adding more recent information.

During the COVID-19 pandemic, psychiatrists must continue to care for their

proven treatments, potential harms of vaccines, and protective measures. Of course, psychiatrists should safeguard their own health with proper nutrition, sleep, rest and exercise, and promptly seek professional help if they become physically or mentally unwell⁵.

Prioritizing Physician Mental Health as COVID-19 Marches On

Some health care professionals, working long hours in life-threatening conditions, often without appropriate protective equipment, may develop anxiety, depression, post-traumatic stress disorder (PTSD), insomnia, and excessive irritability and anger^{3,4,6}. Psychiatrists should assist in devel-....

supports.

As leaders in their hospitals, health care agencies and communities, psychiatrists may also participate in COVID-19 decisionmaking committees (including triage), where they should safeguard the rights of persons with mental disorders. They may participate in educational and media activities for patients, health care workers, the public or policy makers about the mental health distress caused by physical distancing, home quarantine, shelter-in-place, isolation, and loss of social support, work and income3,7. Psychiatrists should also advo-. .

510

Long-COVID symptoms and signs

People hospitalised during acute phase of Covid-19


Based on 26 studies with 7147 people*



People non-hospitalised during acute phase of Covid-19


Based on 4 studies with 1168 people*





Raveendran et al. Long COVID: An overview. Diabetes Metab Syndr. 2021 May-Jun;15(3):869-875. Michelen et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021 Sep;6(9):e005427.

Approach to patients with Long COVID



Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview [published correction appears in Diabetes Metab Syndr. 2022 May 13;:102504]. Diabetes Metab Syndr. 2021;15(3):869-875.

Aging Clinical and Experimental Research https://doi.org/10.1007/s40520-020-01616-x

POINT OF VIEW

Check for updates

Post-COVID-19 global health strategies: the need for an interdisciplinary approach

Gemelli Against COVID-19 Post-Acute Care Study Group¹




Pneumology Brain -Second and a second and a secon Neurological symptoms and psychological Lungs - Groundsglass opacity and/or consolidations, exercise tolerance Liver - High enzyme levels (direct action of Dphthalmolog. virus or drugs side effects) Gut - Virus can infect lower gastrointestinal tract Muscle -Immobilization, Stadiojeuninand malnutrition, sarcopenia and disability **INTERNAL** MEDICINE **GERIATRIC**

Infection Eyes -Impairment of retinal vasculvizationasal obstruction, dysosmia and dysgeusia Heart – Cardiac inflammation, congestive heart failure **Kidneys** – Renal failure Blood vessels - Blood clots and endothelial dysfunction Inflammation -Elevated levels of inflammation-inducing cytokines


13010131

ychiatry Utolary


Sintomi medici persistenti in pazienti Post Covid-19



Ha mai sofferto di ansia, depressione, esaurimenti nervosi, dipendenza da sostanze? C'è qualcuno in famiglia che ha mai sofferto di ansia, depressione, esaurimenti nervosi, dipendenza da sostanze?




Sintomi psichiatrici in pazienti Post Covid-19



Pazienti che hanno fatto riferimento al Day Hospital Post-Covid-19 del Policlinico Agostino Gemelli (età media: 55 anni) Depressione valutata tramite Hamilton Depression Rating Scale


Sani et al, unpublished data

PTSD criteria DSM-5




PTSD in pazienti Post Covid-19

Figure. Posttraumatic Stress Disorder (PTSD) After COVID-19 Infection and Other Collective Traumatic Events




Janiri et al, JAMA Psychiatry 2021

Long COVID: pathophysiological mechanisms



Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview [published correction appears in Diabetes Metab Syndr. 2022 May 13;:102504]. Diabetes Metab Syndr. 2021;15(3):869-875.

COVID-19 and mood disorders: a bidirectional association



Taquet M, et al. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. *Lancet Psychiatry*. 2021 Feb;8(2):130-140.

Taquet M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry*. 2021 May;8(5):416-427.

Risk factors for the onset of depressive symptoms after SARS-CoV-2 infection

Gender: female

- Previous psychiatric history: depression and other mental disorders
- Persistence of psychopathology at one-month follow-up
- Systemic inflammation: measured by platelet count, levels of neutrophils and lymphocytes (e.g., NLR, PLR, Systemic Immune-inflammatory Index, SII)

Renaud-Charest, O., et al., & McIntyre, R. S. (2021). Onset and frequency of depression in post-COVID-19 syndrome: A systematic review. Journal of psychiatric research, 144, 129–137.

Post-COVID-19 depression: onset and frequency

Systematic review: 316 articles screened

→ 8 studies included

Post-COVID-19 patients



3-12%

Depressive symptoms >12 weeks later


Clinically-significant and/or severe depressive symptoms

The severity of acute COVID-19 was not associated with the frequency of depressive symptoms.

Renaud-Charest, O., et al., & McIntyre, R. S. (2021). Onset and frequency of depression in post-COVID-19 syndrome: A systematic review. Journal of psychiatric research, 144, 129–137.

Post-acute COVID-19 neuropsychiatric sequelae: *'long lasting'* depression

A prospective cohort study (N=226 COVID-19 pneumonia survivors, 149 males, mean age 58 years) evaluated the psychopathological status at one- and three-months post-discharge.



Mazza MG, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. *Brain Behav Immun.* 2021 May;94:138-147.

Characteristic features

□ Evidence suggests a central role of depressive psychopathology, which seems to be one of the most relevant predictors of both cognitive impairment (specifically, executive functions and psychomotor coordination) and fatigue, which persist over time in almost a third of COVID-19 survivors.

Ceban F et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. *Brain Behav Immun.* 2022 Mar;101:93-135.

Specific features of post-COVID-19 depression

A meta-analysis on COVID-19 consequences indicate that **32%** of individuals experience **fatigue** and **22%** exhibit **cognitive impairment** 12 or more weeks following infection.


Regardless of clinical physical severity, post-COVID **depression** was found to **possibly affect**:

- □ fatigue symptoms;
- cognitive functions (with poor performances in at least one cognitive domain and specific impairment of executive functions and psychomotor coordination);
- □ daily functioning.

Mazza MG, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. *Brain Behav Immun.* 2021 May;94:138-147; Mazza MG, et al. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. *Eur Neuropsychopharmacol.* 2022 Jan;54:1-6; Ceban F, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. *Brain Behav Immun.* 2022 Mar;101:93-135.


The role of inflammatory biomarkers in predicting persistence of neuropsychiatric symptoms

COVID-19 could result in **prolonged systemic inflammation** (as for values of Systemic Immune-inflammatory Index, SII) that predisposes patients to **persistent depression** and associated neurocognitive dysfunction.



Mazza MG, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. *Brain Behav Immun.* 2021 May;94:138-147.

Anti-inflammatory add-on treatment as new promising strategies in MDD



Meyer JH, Cervenka S, Kim MJ, Kreisl WC, Henter ID, Innis RB. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. *Lancet Psychiatry*. 2020;7(12):1064-1074.

Anti-inflammatory and antiviral properties of antidepressants

A Intention-to-treat analysis 40 Relative risk 95% BCI 0.68 (0.52-0.88) Group Probability (superiority) Fluvoxamine 99.8% Placebo 0.2% 30 Group Fluvoxamine Posterior density 3 Placebo Density 20 Placebo-controlled 2. randomized trial: 10 1 Fluvoxamine group, 0.75 1.25 0.175 1.00 0.075 0.100 0.125 0.150 0.200 0.50 (100)**N**=741 mg Relative risk Event rate B Modified intention-to-treat analysis twice daily for 10 40 ς-Relative risk 95% BCI 0.69 (0.53-0.90) Group Probability (superiority) Fluvoxamine 99.7% days) Placebo 0.3% 4 30 VS. osterior density 3 Density 20 Placebo, N=756 2 -10 -1.25 0.50 0.75 1.00 0.075 0.100 0.125 0.150 0.175 0.200


Reis G, et al.; TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022 Jan;10(1):e42-e51.

Event rate

Relative risk

Post-COVID-19 depression: treatment options


N=60 patients with MDE treated with SSRI in the 6 months after COVID recovery



SSRIs treatment could contribute to the rapid antidepressant response by directly targeting the neuroinflammation triggered by SARS-CoV-2


Mazza, M. G., Zanardi, R., Palladini, M., Rovere-Querini, P., & Benedetti, F. (2022). Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 54, 1–6.

Emerging evidence about the role of antidepressants in SARS-CoV-2 treatment




Xiong HL, et al. Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro. Front Pharmacol. 2021 Feb 5;11:609592. Reis G, et al.; TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022 Jan;10(1):e42-e51.

Immunomodulatory properties of Vortioxetine



Effect on NF- κ B activity and TNF α secretion in PMA-stimulated cells.




Talmon M, et al. Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. Br J Pharmacol. 2018 Jan;175(1):113-124.

Talmon M, et al. Design, synthesis and biological evaluation of vortioxetine derivatives as new COX-1/2 inhibitors in human monocytes. Bioorg Med Chem. 2020 Dec 1;28(23):115760.

The effect on depressive symptoms after threemonths treatment

***p*=0.007



N=50 patients (49.4% M, 52.1 \pm 17.6 years) with moderate depression (DSM-5 criteria, Hamilton Depression Rating Scale \geq 14) New-onset 44.3% vs Recurrent 55.7%


Vortioxetine mean dose: 9.54±3.80 mg/die

Physical features and **fatigue**, **cognitive performances** and **functioning** were retrospectively evaluated through:


- Physical sub-items of HDRS (6.87±2.23) and HARS (7.34±3.8)
- SF-36 Energy/Vitality Subscale (36.1 ± 17.9)
- $\square SF-36 Mental Component Score (33\pm10.6)$
- **PDQ-D5** (10.4 ± 4.74)
- **DSST** (41.6 ± 12.4)

Effects on fatigue and physical correlates

p*=0.049, *p*=0.006, ****p*<0.001



Effects on cognition and functioning



Changes in inflammatory levels

- C Reactive Protein (CRP) levels and Systemic-Immune-Inflammatory Index (SII) were assessed to evaluate the effect of vortioxetine on inflammatory levels underlying post-COVID-19 MDE
- CRP levels and SII showed a decreasing trend after treatment, yet not statistically significant

Inflammatory levels	
PCR (mg/L)	
Baseline	14.1 (40.1)
Endpoint	3.88 (3.9)
SII	
Baseline	505 (372)
Endpoint	372 (185)

Di Nicola M et al. Cognitive impairment in post-covid-19 patients with major depressive episodes: a three-months study on the effect of vortioxetine. Poster at ECNP, 35th European College of Neuropsychopharmacology Congress, Vienna

Clinical and research recommendations

- Peripheral inflammation and neuroinflammation are crucial in the development of depression
- Clinical characterization of all depressive episodes based on a differential association with immune-metabolic dysregulation and identification of markers easy-to-use in common clinical practice, is necessary
- □ Given the prevalence of post-COVID syndrome, assessing psychopathology of COVID-19 survivors is mandatory to promptly diagnose emergent depression
- Targeted pharmacological treatment, possibly affecting inflammatory aspects, are warranted to reduce the disease burden and related years of life lived with disability and to allow full remission and functional recovery